Skip to main content
SpringerLink
Log in

Overexpression of Cyclin A Overrides the Effect of p53 Alterations in Breast Cancer Patients with Long Follow-up Time

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The tumour suppressor gene p53 and its protein controls critical cellular functions in cell cycle regulation as well as in apoptosis. Recently, in an in vitro study on breast cancer cell line MCF-7, the apoptotic function of p53 has been shown to be altered by overexpression of cyclin A. In this study we have demonstrated a similar association in a consecutive series of 166 breast cancer patients operated for invasive breast carcinomas. We detected mutations (exon 5–8) in the tumour tissue from 28 (16.0%) of the patients, and positive immunoreactivity of p53 protein was detected in tumour tissue samples from 32 (18.8%) patients. A statistically significant correlation between TP53 gene mutations and positive immunohistochemistry of p53 protein was observed (p = 0.0038). Mutations of the TP53 gene, as well as positive immunoreactivity to p53, were associated with poor prognosis (mutations p = 0.053, HR = 1.8, 95% CI 0.99–3.4; positive immunoreactivity p = 0.029, HR 1.33, 95% CI 1.0–1.7; mutation and/or positive immunoreactivity p = 0.015, HR 2.1, 95% CI 1.2–3.7) when cyclin A was not included in the survival analysis. However, when cyclin A overexpression was included, alteration of the p53 protein (mutations and/or positive immunoreactivity) lost its statistical power (p = 0.088). In a stratified survival analysis the OR fell from 3.0 (95% CI 1.2–8.3, p = 0.03) in the low-expression cyclin A stratum to 1.3 (95% CI 0.42–4.1, p = 0.77) in the overexpression cyclin A stratum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akselsen LA, Borresrn-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 61: 2505-2512, 2001

    Google Scholar 

  2. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer I 85: 200-206, 1993

    Google Scholar 

  3. Andersen TI, Borresen AL: Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn Mol Pathol 4: 203-211, 1995

    Google Scholar 

  4. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029-1034, 1995

    Google Scholar 

  5. Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M, Tominaga T: Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. Int J Oncol 12: 1117-1125, 1998

    Google Scholar 

  6. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993

    Google Scholar 

  7. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, Zhong S, Lu X: Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol 22: 78-93, 2002

    Google Scholar 

  8. Rosenblatt J, Gu Y, Morgan DO: Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. P Natl Acad Sci USA 89: 2824-2828, 1992

    Google Scholar 

  9. Walker DH, Maller JL: Role for cyclin A in the dependence of mitosis on completion of DNA replication. Nature 354: 314-317, 1991

    Google Scholar 

  10. Pagano M, Pepperkok R, Verde F, AnsorgeW, Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J 11: 961-971, 1992

    Google Scholar 

  11. Faha B, Ewen ME, Tsai LH, Livingston DM, Harlow E: Interaction between human cyclin A and adenovirus E1Aassociated p107 protein. Science 255: 87-90, 1992

    Google Scholar 

  12. Bandara LR, Adamczewski JP, Hunt T, La Thangue NB: Cyclin A and the retinoblastoma gene product complex with a common transcription factor. Nature 352: 249-251, 1991

    Google Scholar 

  13. Mudryj M, Devoto SH, Hiebert SW, Hunter T, Pines J, Nevins JR: Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A. Cell 65: 1243-1253, 1991

    Google Scholar 

  14. Volm M, Koomagi R, Mattern J, Stammler G: Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Brit J Cancer 75: 1774-1778, 1997

    Google Scholar 

  15. Chao Y, Shih YL, Chiu JH, Chau GY, Lui WY, Yang WK, Lee SD, Huang TS: Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res 58: 985-990, 1998

    Google Scholar 

  16. Handa K, Yamakawa M, Takeda H, Kimura S, Takahashi T: Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 84: 225-233, 1999

    Google Scholar 

  17. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K, Kosma VM: Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Brit J Cancer 80: 2001-2007, 1999

    Google Scholar 

  18. Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R: Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195: 530-536, 2001

    Google Scholar 

  19. Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van Diest P: Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Brit J Cancer 86: 402-408, 2002

    Google Scholar 

  20. Bukholm IR, Bukholm G, Nesland JM: Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 93: 283-287, 2001

    Google Scholar 

  21. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991

    Google Scholar 

  22. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL: Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 181: 140-145, 1997

    Google Scholar 

  23. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J: Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 9: 348-355, 1997

    Google Scholar 

  24. Borresen AL, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH: Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. P Natl Acad Sci USA 88: 8405-8409, 1991

    Google Scholar 

  25. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993

    Google Scholar 

  26. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994

    Google Scholar 

  27. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993

    Google Scholar 

  28. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Forance AJ, Magrath I, Kohn KW, O'Conner PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994

    Google Scholar 

  29. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Brit J Cancer 72: 1259-1266, 1995

    Google Scholar 

  30. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocco D, Ravdin P, O'sullivan J, Rivkin S, Martino S, Osborne CK: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 15: 1916-1922, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Akershus University Hospital, Nordbyhagen, Norway

    Ida RK Bukholm

  2. Institute of Clinical Epidemiology and Molecular Biology, Akershus University Hospital, Nordbyhagen, Norway

    Anne Husdal & Geir Bukholm

  3. University of Oslo, Oslo, Norway

    Anne Husdal, Jahn M. Nesland & Geir Bukholm

  4. Department of Pathology, Institute for Cancer Research, The Norwegian Radium Hospital, Norway

    Jahn M. Nesland

  5. Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Norway

    Anita Langerød

Authors
  1. Ida RK Bukholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Husdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jahn M. Nesland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anita Langerød
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Geir Bukholm
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bukholm, I.R., Husdal, A., Nesland, J.M. et al. Overexpression of Cyclin A Overrides the Effect of p53 Alterations in Breast Cancer Patients with Long Follow-up Time. Breast Cancer Res Treat 80, 199–206 (2003). https://doi.org/10.1023/A:1024527220362

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1024527220362

Search

Navigation